scorecardresearch
Wednesday, July 30, 2025
TopicBiosimilar drugs

Topic: biosimilar drugs

India’s draft guidelines on biosimilar drugs can make treatments more accessible, affordable

Though India has built a robust domestic biosimilar market, its international presence and the ability to lower prices as compared to small molecule generics remain limited.

Don’t let foreign big pharma block biosimilars. Govt should boost access in India

Without widespread access to biosimilars, thousands of cancer patients are losing their battle. Life-saving treatment is not a privilege but a right. The government should understand this.

On Camera

Lord Meghnad Desai belonged to no camp—and, somehow, to every camp at once

Meghnad Desai founded LSE’s Centre for the Study of Global Governance and its Development Studies programme, and had earlier co-created the Human Development Index.

Govt’s earlier FDI limit of 74% in insurance sector has remained underutilised, Parliament told

In the latest budget, the FDI limit was increased to 100 percent, but most foreign companies are not buying such large stakes in the Indian insurance sector.

India’s air defence system foiled 1,000 Pakistani drone attacks on 9 May—Modi tells Parliament

New Delhi: India’s air defence systems intercepted and destroyed 1,000 drones and missiles launched by Pakistan on 9 May during Op Sindoor, Prime Minister...

Modi’s Bharat vs Indira’s India: 11-yr report card of politics, diplomacy, economy, nationalism

As Narendra Modi becomes India’s second-longest consecutively serving Prime Minister, we look at how he compares with Indira Gandhi across four key dimensions.